Rosetta Genomics Ltd. is a molecular diagnostics company engaged in developing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has established a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in Philadelphia, which enables it to commercialize its diagnostic tests applying its microRNA technology. It has developed platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, cardiovascular diseases and other indications. The Company’s products are Rosetta Cancer Origin Test (formerly miRview mets2), Rosetta Mesothelioma Test (formerly miRview meso), Rosetta Lung Cancer Test (formerly miRview lung) and Rosetta Kidney Cancer Test (formerly miRview kidney).